of non-direct anti-viral medications on COVID-19 patients. A group of these trials has
investigated the effect of antiplatelets, including aspirin and/or P2Y12 inhibitors (P2Y12i),
including three recently published trials in the past two months: ACTCOVID19 (Anti-Coronavirus
Therapies to Prevent Progression of COVID-19) [ … In conclusion, in treating COVID-19
patients, our study did not find significant benefit from adding antiplatelets in terms of mortality …